NEW YORK (GenomeWeb) – In an effort to systematically characterize major technologies for cancer mutation testing, researchers at AstraZeneca have published an evaluation of 13 assays for KRAS mutations.
NEW YORK (GenomeWeb) – In an effort to systematically characterize major technologies for cancer mutation testing, researchers at AstraZeneca have published an evaluation of 13 assays for KRAS mutations.
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.